JP6002128B2 - プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 - Google Patents

プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 Download PDF

Info

Publication number
JP6002128B2
JP6002128B2 JP2013518766A JP2013518766A JP6002128B2 JP 6002128 B2 JP6002128 B2 JP 6002128B2 JP 2013518766 A JP2013518766 A JP 2013518766A JP 2013518766 A JP2013518766 A JP 2013518766A JP 6002128 B2 JP6002128 B2 JP 6002128B2
Authority
JP
Japan
Prior art keywords
protein
spa
staphylococcal
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013518766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534532A (ja
JP2013534532A5 (fr
Inventor
オラフ シュニーウィンド
オラフ シュニーウィンド
アリス ジー． チェン
アリス ジー． チェン
ドミニク エム． ミシアカス
ドミニク エム． ミシアカス
ファン キム
ファン キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2013534532A publication Critical patent/JP2013534532A/ja
Publication of JP2013534532A5 publication Critical patent/JP2013534532A5/ja
Application granted granted Critical
Publication of JP6002128B2 publication Critical patent/JP6002128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013518766A 2010-07-02 2011-07-01 プロテインＡ（ＳｐＡ）変種に関連する組成物および方法 Active JP6002128B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36121810P 2010-07-02 2010-07-02
US61/361,218 2010-07-02
US37072510P 2010-08-04 2010-08-04
US61/370,725 2010-08-04
PCT/US2011/042845 WO2012003474A2 (fr) 2010-07-02 2011-07-01 Compositions et méthodes associées à des variants de protéine a (spa)

Publications (3)

Publication Number Publication Date
JP2013534532A JP2013534532A (ja) 2013-09-05
JP2013534532A5 JP2013534532A5 (fr) 2014-05-08
JP6002128B2 true JP6002128B2 (ja) 2016-10-05

Family

ID=45402686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518766A Active JP6002128B2 (ja) 2010-07-02 2011-07-01 プロテインＡ（ＳｐＡ）変種に関連する組成物および方法

Country Status (12)

Country Link
US (7) US8821894B2 (fr)
EP (1) EP2588120B1 (fr)
JP (1) JP6002128B2 (fr)
KR (1) KR20130093084A (fr)
CN (1) CN103037885B (fr)
AU (1) AU2011274367B2 (fr)
BR (1) BR112013000097B1 (fr)
CA (1) CA2803298C (fr)
ES (1) ES2655701T3 (fr)
SG (1) SG186290A1 (fr)
WO (1) WO2012003474A2 (fr)
ZA (1) ZA201209561B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
BRPI1010307B1 (pt) * 2009-04-03 2021-07-27 University Of Chicago Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
RS56000B1 (sr) * 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
CN103037885B (zh) * 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
WO2012034067A1 (fr) * 2010-09-09 2012-03-15 The University Of Chicago Procédés et compositions impliquant des antigènes staphylococciques protecteurs
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
JP6317670B2 (ja) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
CA2910320A1 (fr) 2012-04-26 2013-10-31 University Of Chicago Compositions et procedes associes a des anticorps qui neutralisent l'activite coagulase dans une maladie a staphylococcus aureus
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2015085463A1 (fr) * 2013-12-09 2015-06-18 重庆原伦生物科技有限公司 Mutant spa5 de staphylococcus aureus, composition comprenant le mutant et procédé de préparation et d'utilisation associé
CN105407905B (zh) 2014-01-03 2020-03-03 生物辐射实验室股份有限公司 蛋白a洗脱产物中杂质的去除
TWI709571B (zh) 2015-03-26 2020-11-11 日商Ｊｓｒ股份有限公司 免疫球蛋白結合蛋白質及使用此之親和性載體
WO2017137954A2 (fr) 2016-02-12 2017-08-17 The University Of Chicago Compositions et procédés associés à des anticorps qui neutralisent une activité de coagulase en cas de maladie à staphylocoque doré
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
EP3521304B9 (fr) 2018-02-01 2023-10-04 Repligen Corporation Protéines de liaison fc avec la cystéine dans la région hélicoïdale c-terminale
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2020273471A1 (en) * 2019-05-14 2021-12-23 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
CN117700501A (zh) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 免疫球蛋白结合蛋白及其应用

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
GB1499035A (en) 1975-04-10 1978-01-25 Ts Nii Gematologii I Perelivan Antistaphylococcus human immune globulin and method of preparing same
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4327082A (en) 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US5151350A (en) 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
CA2059693C (fr) 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
WO1993018784A1 (fr) 1992-03-26 1993-09-30 Microcarb, Inc. Anticorps polyclonaux monospecifiques des toxines de type shiga
US5217277A (en) 1992-05-11 1993-06-08 The Berkline Corporation Seat arm with concealed table
EP1983056A1 (fr) 1992-07-07 2008-10-22 Japan Tobacco Inc. Procédé de transformation de monocotylédones
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
BR9306802A (pt) 1992-07-27 1998-12-08 Pioneer Hi Bred Int Processo independente de genótipos para produção de planta de soja transgénica e processo de regeneração de plantas de soja a partir de nodos cotiledonais
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
WO1994006830A1 (fr) 1992-09-21 1994-03-31 Alfa-Laval Agri International Aktiebolag Proteine de liaison du fibrinogene
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO1995033073A1 (fr) 1994-05-28 1995-12-07 Tepnel Medical Limited Production de copies d'acides nucleiques
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
WO1997014800A1 (fr) 1995-10-16 1997-04-24 Smithkline Beecham Plc Nouvelle proteine fixant la salive
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6403337B1 (en) 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6833253B2 (en) 1996-01-05 2004-12-21 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and polypeptides
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
FR2746398B1 (fr) 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
AU3126097A (en) 1996-05-16 1997-12-05 The Texas A & M University System Collagen binding protein compositions and methods of use
US6013763A (en) 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
BR9712366A (pt) 1996-10-23 1999-08-31 American Home Prod Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
EP1097212B1 (fr) 1998-07-10 2008-12-24 U.S. Medical Research Institute of Infectious Diseases Vaccin du charbon bacteridien
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
EP1121149A4 (fr) 1998-08-31 2002-03-20 Inhibitex Inc Procede d'immunotherapie contre les infections staphylococciques comprenant la selection des donneurs et la stimulation des donneurs
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
CN1283798C (zh) 1998-08-31 2006-11-08 都柏林伊丽莎白女皇神学院 凝固酶阴性葡萄球菌的多肽及多核苷酸
ES2322409T3 (es) 1998-08-31 2009-06-19 Inhibitex, Inc. Vacunas multicomponentes contra staphylococcus aureus.
EP1109911A4 (fr) 1998-09-01 2005-04-27 Human Genome Sciences Inc Genes de staphylococcus aureus et polypeptides associes
DK1121135T3 (da) 1998-09-14 2009-03-23 Nabi Biopharmaceuticals Præparater af beta-glucaner og specifikke immunglobuliner
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AU4810600A (en) 1999-04-28 2000-11-10 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Method of inhibiting leukocyte adhesion to fibrinogen
WO2000071585A1 (fr) 1999-05-03 2000-11-30 Medarex, Inc. Anticorps humains diriges contre le staphylococcus aureus
AU777005B2 (en) * 1999-05-15 2004-09-30 University Of California, San Diego Protein A based binding domains with desirable activities
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2001034809A2 (fr) 1999-11-09 2001-05-17 Glaxo Group Limited Acides nucleiques et proteines de staphylococcus epidermidis
WO2001039803A2 (fr) 1999-12-03 2001-06-07 Celltech Chiroscience Ltd. Muteines de l'interleukine 1 utiles comme adjuvants de vaccins
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
CA2403359A1 (fr) 2000-03-17 2001-09-27 Inhibitex, Inc. Anticorps de deplacement a reaction croisee provenant des proteines de liaison du collagene et procede d'identification et d'utilisation
JP4852211B2 (ja) 2000-03-21 2012-01-11 メルク アンド カンパニー インコーポレイテッド 原核生物における必須遺伝子の同定
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
SE0003573D0 (sv) 2000-10-04 2000-10-04 Bengt Guss Method and means for producing novel von Willebrand factor binding proteins and their use in biotechnology
AU1486102A (en) 2000-11-07 2002-05-21 Immunovaccine Technologies Inc Vaccines with enhanced immune response and methods for their preparation
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002074324A1 (fr) 2001-03-15 2002-09-26 The Texas A & M University System Adhesine se fixant au collagene issue de staphylococcus epidermidis et procede d'utilisation
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1443957A4 (fr) 2001-05-08 2005-10-12 Texas A & M Univ Sys Proteines de surface issues de bacteries gram positif comportant des motifs fortement conserves et anticorps reconnaissant ces motifs
EP2339344A1 (fr) 2001-06-15 2011-06-29 Inhibitex, Inc. Anticorps monoclonaux et polyclonaux à réaction croisée qui reconnaissent des protéines de surface de staphylocoques à coagulase négative et de staphylocoques dores
CA2351018A1 (fr) 2001-07-09 2003-01-09 Universite De Sherbrooke Vaccin a adn contre staphylococcus aureus
US7410647B2 (en) 2001-08-02 2008-08-12 University Of Sheffield Antigenic polypeptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US7115264B2 (en) 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
WO2003041726A1 (fr) 2001-11-16 2003-05-22 Biostapro Ab Utilisation d'une proteine d'adherence extracellulaire pour la fabrication d'un anti-inflammatoire
ATE419005T1 (de) 2001-12-11 2009-01-15 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren
EP1481011A4 (fr) 2002-03-05 2007-05-30 Inhibitex Inc Anticorps monoclonaux et polyclonaux reconnaissant des proteines staphylocoques a coagulase negative
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
WO2004025416A2 (fr) 2002-09-13 2004-03-25 The Texas A & M University System Procede bio-informatique destine a identifier les proteines ancrees en surface provenant des bacteries gram positif et proteines obtenues par ce procede
AU2003249851A1 (en) 2002-10-03 2004-04-23 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
DK1565478T3 (da) 2002-11-12 2017-11-13 Brigham & Womens Hospital Inc Polysaccharidvaccine mod stafylokokinfektioner
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2004048975A1 (fr) 2002-11-22 2004-06-10 Daiichi Pure Chemicals Co., Ltd. Procede de detection de staphylococcus aureus
JP2007525446A (ja) 2003-03-28 2007-09-06 エルシス セラピューティクス， インク． 抗体活性の転換のための方法及び組成物
US20070053925A1 (en) 2003-04-16 2007-03-08 Eric Brown Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20060065643A (ko) 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
CA2555342A1 (fr) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides d'induction d'une reponse immune protectrice contre staphylococcus aureus
US7284284B2 (en) 2004-06-15 2007-10-23 James Wysopal Headgear article incorporating a bottle opener
US20080095792A1 (en) 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
KR20070085457A (ko) 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법
AU2005302312A1 (en) 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US8398991B2 (en) 2005-06-22 2013-03-19 Institut Pasteur Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
WO2007089470A2 (fr) 2006-01-27 2007-08-09 Merck & Co., Inc. Protéines de liaison à l'antigène ciblant l'orf0657n de s. aureus
WO2007095057A2 (fr) 2006-02-10 2007-08-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Méthodes pour traiter et prévenir des maladies auto-immunes neuro-inflammatoires
EP1996231A4 (fr) 2006-02-22 2010-09-15 Texas A & M Univ Sys Anticorps reconnaissant un antigène putatif hautement exprimé du sarm-c et procédés d'utilisation
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
WO2008152447A2 (fr) 2006-10-30 2008-12-18 The University Of Western Ontario Anti-infectieux spécifiques de staphylococcus aureus
WO2008140487A2 (fr) 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Molecules ameliorees se liant a la proteine a staphylococcique, heteropolymeres les contenant et methodes d'utilisation associees
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US20100047252A1 (en) 2006-11-22 2010-02-25 3M Innovative Properties Company Antibody with protein a selectivity
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2009029132A2 (fr) 2007-05-31 2009-03-05 Merck & Co., Inc. PROTÉINES DE LIAISON À L'ANTIGÈNE CIBLANT L'ORF0657n DE S. AUREUS
WO2009029831A1 (fr) 2007-08-31 2009-03-05 University Of Chicago Procédés et compositions associées pour immuniser contre des maladies et des états staphylococciques des poumons
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009140236A2 (fr) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Préparations d'anticorps spécifiques de staphylococcus aureus
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
EP2382234A2 (fr) 2008-12-23 2011-11-02 Genentech, Inc. Variantes d'immunoglobuline de propriétés de liaison vis-à-vis de la protéine a altérées
BRPI1010307B1 (pt) 2009-04-03 2021-07-27 University Of Chicago Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
MY169837A (en) 2009-06-22 2019-05-16 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012122533A2 (fr) 2011-03-10 2012-09-13 The University Of Chicago Compositions et procédés liés à des anticorps contre les protéines staphylococciques isda ou isdb
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
JP2013523818A (ja) * 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
CN103037885B (zh) * 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
WO2012034067A1 (fr) * 2010-09-09 2012-03-15 The University Of Chicago Procédés et compositions impliquant des antigènes staphylococciques protecteurs
WO2012034077A2 (fr) 2010-09-09 2012-03-15 The University Of Chicago Compositions et procédés relatifs à des souches de staphylocoques atténuées
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides

Also Published As

Publication number Publication date
EP2588120A2 (fr) 2013-05-08
US20130171183A1 (en) 2013-07-04
US11059866B2 (en) 2021-07-13
WO2012003474A3 (fr) 2012-04-05
BR112013000097B1 (pt) 2022-02-01
ZA201209561B (en) 2016-10-26
US9315554B2 (en) 2016-04-19
SG186290A1 (en) 2013-01-30
ES2655701T3 (es) 2018-02-21
US20200140494A1 (en) 2020-05-07
EP2588120A4 (fr) 2014-03-26
US11939358B2 (en) 2024-03-26
CA2803298C (fr) 2020-07-14
WO2012003474A2 (fr) 2012-01-05
AU2011274367B2 (en) 2015-04-23
CN103037885A (zh) 2013-04-10
EP2588120B1 (fr) 2017-11-15
CA2803298A1 (fr) 2012-01-05
US8821894B2 (en) 2014-09-02
AU2011274367A1 (en) 2013-01-10
US10464971B2 (en) 2019-11-05
US20150056240A1 (en) 2015-02-26
US20170369536A1 (en) 2017-12-28
JP2013534532A (ja) 2013-09-05
US20160194363A1 (en) 2016-07-07
US20240190927A1 (en) 2024-06-13
CN103037885B (zh) 2015-08-26
KR20130093084A (ko) 2013-08-21
BR112013000097A2 (pt) 2017-05-16
US20210290748A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
JP6002128B2 (ja) プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
JP6042574B2 (ja) 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
JP5793194B2 (ja) 感染防御ブドウ球菌抗原が関与する方法および組成物
JP5789250B2 (ja) プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
JP2018121640A (ja) ブドウ球菌コアグラーゼ抗原およびその使用方法
JP2022533096A (ja) ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140317

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160902

R150 Certificate of patent or registration of utility model

Ref document number: 6002128

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250